Tag: Novartis
Novartis: approval in hidradenitis suppurativa
(CercleFinance.com) – Novartis announces that the United States FDA has approved its Cosentyx (secukinumab) for the treatment in adults of moderate to severe forms of hidradenitis suppurativa, a chronic skin…
Novartis: Positive data in nephropathy
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Novartis: positive data in nephropathy
(CercleFinance.com) – Novartis announces positive initial results from the interim analysis of the ongoing pivotal phase III ALIGN study of atrasentan, an oral endothelin A receptor (ERA) antagonist, in patients…
Novartis once again raises its outlook for 2023
Published on 10/24/2023 at 9:09 a.m. Photo credit © Reuters FRANKFURT (Reuters) – Novartis raised its full-year…
Novartis: promising data in prostate cancer
(CercleFinance.com) – Novartis announced Monday that a phase III trial of Pluvicto in the treatment of metastatic prostate cancer had met its primary endpoint. The study showed that Pluvicto reduced…
Worth eleven billion francs: Novartis subsidiary Sandoz begins its stock market career
Worth eleven billion francs Novartis subsidiary Sandoz begins stock market career October 4, 2023, 2:02 p.m The Swiss pharmaceutical giant Novartis is restructuring and will focus on patent-protected drugs in…
Novartis: The sale of ophthalmological assets is completed
(CercleFinance.com) – Novartis announced on Friday that it had finalized the sale of its assets linked to the ‘surface of the eye’, sold to the American Bausch + Lomb as…
Novartis: the sky clears with the confirmation of the Sandoz split on October 4
(AOF) – Novartis (+0.07% to 92 Swiss francs) today confirmed its plan to spin off 100% of the Sandoz business. Trading of new Sandoz Group AG shares and ADRs (American…
Novartis: Sandoz split confirmed for October 4
(CercleFinance.com) – Novartis confirms its plans for the 100% spin-off of Sandoz, its generic and biosimilar medicines division, with the trading of new shares and ADRs (American Depositary Receipts) in…
Novartis: Sandoz split confirmed for October 4
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Novartis: Favorable opinion for a trastuzumab biosimilar
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Novartis: favorable opinion for a trastuzumab biosimilar
(CercleFinance.com) – Sandoz, the generic subsidiary of Novartis, announced Monday that the committee of experts (CHMP) of the European Medicines Agency (EMA) had issued a favorable opinion concerning its marketing…